Anticancer Gold Compounds


Gold(III) complexes (Au1) demonstrate potential as targeted chemotherapeutics for combating advanced stage cancer

  • Anticancer Gold Compounds 0
Commercialisation opportunities
LSCCB, HKU and start-up company GoldPorp Pharma Ltd are developing the proprietary anticancer metal compounds with possibility of collaborative research projects and licensing.
Problem addressed

Despite advances in new modalities of cancer therapy, chemotherapy may be unavoidably used for those advanced cancer patients who fail to respond to targeted therapy and immunotherapy. Au1 show proven anticancer activities and hold promise as targeted chemotherapeutics.

  • Au1 exhibit effective anticancer activities in patient derived tumour organoids and mice models of diversified human cancer types including liver, colon, nasopharyneal, ovarian and lung carcinoma
  • Au1 suppress orthrotopic hepatocellular carcinoma growth and impede metastatic spread to lung in mice.
  • PEGylated Au1 having improved safety pharmacology profile show significant inhibition in the tumour growth in mice bearing EBV+ve nasopharyneal carcinoma xenograft.
  • Antibody-drug conjugate of Au1 for improving tumor delivery has been developed.
Key impact
  • Au1 target anticancer molecular targets (e.g. heat shock protein, aminopeptidase, thioredoxin) that lack therapeutic inhibitors.
  • Au1 exhibit effective anti-tumor activities and impede metastasis in advanced stage cancer models.
  • Au1 are desirable payloads of drug-targeting conjugates and lipid nanoparticle formulations which show marked shrinking effects on targeted tumours in mice.
  • Investigational New Drug application in preparartion


  • US11,135,310
  • ZL201680081386.0
  • EP3386986

Laboratory for Synthetic Chemistry and Chemical Biology (LSCCB) is an R&D centre funded by Health@InnoHK progamme of Innovation and Technology Commission of  HKSAR. Established in 2020, LSCCB is operated with tripartite joint collaboration of The University of Hong Kong, Imperial College London and Peking University. LSCCB aims at integrating chemical and biomedical sciences to develop new molecular medicines and diagnostic tools for the treatment and analysis of human diseases, in particular, cancer. LSCCB currently assembles more than 20 principal investigators for 4 major research programmes including (a) Synthetic Chemistry; (b) Chemical Biology of Natural Products and Chinese Medicine; (c) Metal Anticancer Medicine, Diagnostics and Theranostics; and (d) Multi-Omics and Innovative Analytical Technologies for InnoHealth.